Global and targeted serum metabolic profiling of colorectal cancer progression

Yin, Lu; Sánchez-Espiridión, Beatriz; Lin, Moubin; White, Lindsey; Mishra, Lopa; Raju, Gottumakkala S.; Kopetz, Scott; Eng, Cathy; Hildebrandt, Michelle A.T.; Chang, David W.; Ye, Yuanqing; Liang, Dong; Wu, Xifeng

doi:10.1002/cncr.30829

Cited by 57 publications

(64 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypoxanthine has been previously reported to be increased in tumor tissue of colorectal cancer patients compared to normal tissue of healthy individuals. 15 In contrast, a recent study, 20 Like taurine, 5 hypoxanthine is an antioxidant and increased levels reported in our study may be the result of increased oxidative stress, 28 which is recognized as an important process in carcinogenesis, including colorectal cancer. 29,30 Inconsistent findings in hypoxanthine levels may be due to the type of specimen analyzed, or lack of statistical power because of lower sample numbers included.…”

Section: Discussioncontrasting

confidence: 92%

“…In contrast, a recent study, published by Long et al . reported decreased levels of hypoxanthine in colorectal cancer and polyps compared to controls . Like taurine, hypoxanthine is an antioxidant and increased levels reported in our study may be the result of increased oxidative stress, which is recognized as an important process in carcinogenesis, including colorectal cancer .…”

Section: Discussionsupporting

confidence: 52%

“…Two of these studies investigated metabolic differences between colorectal cancer patients and apparently healthy individuals; a third study evaluated metabolomic differences between matched tumor and healthy colon tissue samples from colorectal cancer patients . In addition, a very recent study investigating metabolic profiles in adenomas, colorectal cancer cases and controls conducted analysis in two datasets utilizing different metabolomic approaches, but with both sample sets deriving from the same hospital and cohort …”

Section: Introductionmentioning

confidence: 99%

“…19 In addition, a very recent study investigating metabolic profiles in adenomas, colorectal cancer cases and controls conducted analysis in two datasets utilizing different metabolomic approaches, but with both sample sets deriving from the same hospital and cohort. 20 To complement current research, we utilized a powerful combination of untargeted metabolomics analysis, able to reveal (novel) metabolites, a rigorous discovery-replication design, leveraging samples deriving from two independent study populations, as well as relatively large sample sizes to obtain sufficient statistical power. The overall purpose of our study was to discover, and replicate plasma metabolites associated with colorectal cancer to improve knowledge regarding potential disease etiology.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Plasma metabolites associated with colorectal cancer: A discovery‐replication strategy

Geijsen

Brezina

Keski‐Rahkonen

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Colorectal cancer is known to arise from multiple tumorigenic pathways; however, the underlying mechanisms remain not completely understood. Metabolomics is becoming an increasingly popular tool in assessing biological processes. Previous metabolomics research focusing on colorectal cancer is limited by sample size and did not replicate findings in independent study populations to verify robustness of reported findings. Here, we performed a ultrahigh performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (UHPLC‐QTOF‐MS) screening on EDTA plasma from 268 colorectal cancer patients and 353 controls using independent discovery and replication sets from two European cohorts (ColoCare Study: n = 180 patients/n = 153 controls; the Colorectal Cancer Study of Austria (CORSA) n = 88 patients/n = 200 controls), aiming to identify circulating plasma metabolites associated with colorectal cancer and to improve knowledge regarding colorectal cancer etiology. Multiple logistic regression models were used to test the association between disease state and metabolic features. Statistically significant associated features in the discovery set were taken forward and tested in the replication set to assure robustness of our findings. All models were adjusted for sex, age, BMI and smoking status and corrected for multiple testing using False Discovery Rate. Demographic and clinical data were abstracted from questionnaires and medical records.

show abstract

Section: Discussioncontrasting

confidence: 92%

Section: Discussionsupporting

confidence: 52%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma metabolites associated with colorectal cancer: A discovery‐replication strategy

Geijsen

Brezina

Keski‐Rahkonen

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…This feature arises from purine degradation that is usually observed in the SERS spectra of incubated blood samples . Interestingly, the level of hypoxanthine in SERS spectrum was reduced in CRC samples when compared with healthy control, which is consistent with the result of metabolomic profiling . The thymine signal at 741 cm −1 is also found to be generally stronger in the healthy group .…”

Section: Resultsmentioning

confidence: 99%

Label‐free diagnosis for colorectal cancer through coffee ring‐assisted surface‐enhanced Raman spectroscopy on blood serum

Yan

Huang

et al. 2020

Journal of Biophotonics

View full text Add to dashboard Cite

Surface-enhanced Raman spectroscopy (SERS) is garnering considerable attention for the swift diagnosis of pathogens and abnormal biological status, that is, cancers. In this work, a simple, fast and inexpensive optical sensing platform is developed by the design of SERS sampling and data analysis. The pretreatment of spectral measurement employed gold nanoparticle colloid mixing with the serum from patients with colorectal cancer (CRC). The droplet of particle-serum mixture formed coffee-ring-like region at the rim, providing strong and stable SERS profiles. The obtained spectra from cancer patients and healthy volunteers were analyzed by unsupervised principal component analysis (PCA) and supervised machine learning model, such as support-vector machine (SVM), respectively. The results demonstrate that the SVM model provides the superior performance in the classification of CRC diagnosis compared with PCA. In addition, the values of carcinoembryonic antigen from the blood samples were compiled with the corresponding SERS spectra for SVM calculation, yielding improved prediction results. K E Y W O R D S colorectal cancer diagnosis, label-free detection, machine learning, nanoparticles, SERS

show abstract

Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study

et al. 2019

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is one of the most common cancers worldwide. Screening for CRC using the fecal occult blood test (FOBT) is feasible and useful for decreasing disease‐related mortality; however, its sensitivity and compliance are unsatisfactory. Methods This study examined the efficacy of using serum placenta growth factor (PlGF) for a novel CRC screening strategy. To investigate a potential novel screening tool for CRC, we compared the sensitivity, specificity, positive predictive value, and negative predictive value of the FOBT, serum PlGF, and their combination through an examination of two independent cohorts and validation using the second cohort. All the patients and control group received the colonoscopy and FOBT, the colonoscopy was used as the gold standard for the result. Results Serum PlGF levels were significantly increased in CRC patients (16.8 ± 11.4 pg/mL) compared with controls (12.0 ± 11.2 pg/mL). The predictive model that used the serum PlGF level alone was as effective as the FOBT (AUC: 0.60 vs 0.68, P = 0.891), and it had significantly higher sensitivity than the FOBT (0.81 vs 0.39). In addition, we found serum PlGF level has a good value for predicting CRC patients in those FOBT negative populations. Finally, combining serum PlGF level and the FOBT improved the predictive power and demonstrated satisfactory sensitivity (0.71) and specificity (0.71). This result was confirmed and validated in the second independent cohort. Furthermore, no matter the stages (early/advanced) and the location (distal/proximal) of CRC, the efficacy of serum PlGF and the combined model remained quite stable. Conclusion Serum PlGF level is a potential alternative screening tool for CRC, especially for those who are reluctant to stool‐based screening methods and who were tested as negative FOBT. In addition, combining serum PlGF level and the FOBT could increase the power of CRC screening.

show abstract

Global and targeted serum metabolic profiling of colorectal cancer progression

Cited by 57 publications

References 33 publications

Plasma metabolites associated with colorectal cancer: A discovery‐replication strategy

Plasma metabolites associated with colorectal cancer: A discovery‐replication strategy

Label‐free diagnosis for colorectal cancer through coffee ring‐assisted surface‐enhanced Raman spectroscopy on blood serum

Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study

Contact Info

Product

Resources

About